Audit: QRS - Topical Ferulic Acid for Skin Rejuvenation

Audit conducted on 29/06/2026 13:46 using AI4L / Opus 4.8

Iterations

Summary

Items	Count
Total	91
Passed	87
Failed	0
N/A	4
Pass Rate	100.00%

• Total = Passed + Failed + N/A
• Pass Rate = Passed / (Passed + Failed) × 100
• N/A items are excluded from the pass rate calculation

Note: [total_items] in the prompt (version 26.5.18) is stated as 71, but the actual checklist contains 91 numbered items (sections 1–15). The audit covers all 91 items present in the checklist.

---

1. General Rules

#	Description	Result	Comments
1.1	Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER.	🟢	All QRS content traces to ER passages (formulation, timing, time-to-effect, benefits, risks, monitoring).
1.2	Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing.	🟢	At-a-glance preserves “independent contribution remains only partly defined” matching ER conclusion.
1.3	The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”).	🟢	No strengthening/softening; “roughly doubling short-term protection” mirrors ER conclusion.
1.4	The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc.	🟢	Contraindications and interactions both drawn from ER Key Interactions & Contraindications; no miscategorization.
1.5	PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact.	🟢	QRS contains no PMIDs, NCTs, expert names, or brand names.
1.6	The QRS does not introduce new attributions.	🟢	No attributions present in the QRS.

2. Focus, Tone & Audience

#	Description	Result	Comments
2.1	The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing.	🟢	Objective, measured tone consistent with ER.
2.2	The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging	🟢	Expert yet accessible throughout.
2.3	The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor	🟢	Presents evidence, not orders.
2.4	The QRS avoids language that implies medical or clinical advice	🟢	No directive medical advice; footer disclaimer present.
2.5	The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising”	🟢	Content is descriptive.
2.6	The QRS never addresses “the reader” directly — it presents evidence, not guidance	🟢	No second-person address.
2.7	The QRS is written in plain language, avoiding unnecessary medical jargon	🟢	Plain language; technical terms minimal and contextual.
2.8	Information is presented in a concise and very compact manner	🟢	Compact cells and lists.
2.9	It DOES NOT address the reader directly	🟢	No “you”/”your”.
2.10	The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review.	🟢	Framing fits proactive optimizer audience.
2.11	The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort.	🟢	Protocol/titration framing assumes willing adopter.
2.12	The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort.	🟢	Not pitched to casual reader.
2.13	Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience.	🟢	Prevention/photoprotection framing reflects the audience.
2.14	The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim.	🟢	Uses “rejuvenation”/”photoaging”; no “anti-aging” misuse.
2.15	The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt.	🟢	Formal terminology used throughout.

3. Template Integrity

#	Description	Result	Comments
3.1	The following labels and headings on the QRS are fixed and not modified: Card/section headings (“Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”); Gate headings (“Contraindications”, “Key Interactions”); Tier labels (“High”, “Medium”, “Low”, “Speculative”); Monitoring column headers (“Marker”, “Target”, “Why”).	🟢	All fixed headings present and unmodified.
3.2	All “…” from the [qrs_template] are present in the the QRS.	🟢	All template spans present (including empty time_3 and hidden high/medium tiers).
3.3	Spans that are not addressed in a checklist item are left unchanged	🟢	No unaddressed spans altered.

4. Formatting

#	Description	Result	Comments
4.1	When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied”	🟢	No ER section feeding the QRS is empty in a way requiring empty-state text; absent tiers handled via display:none per 12.5/13.5.
4.2	Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label.	🟢	Monitoring/qualitative labels match ER bullets.
4.3	Labels are not paraphrased, abbreviated, or invented.	🟢	Labels consistent with ER.
4.4	The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels.	🟢	No emoji indicators in QRS body.
4.5	The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page.	🟢	Content condensed to single-page budget.

5. Metadata

#	Description	Result	Comments
5.1	The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content.	🟢	Metadata comment is first element (lines 2–14).
5.2	Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML.	🟢	YAML delimited by --- (lines 3 and 13).
5.3	The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet.	🟢	Enclosed in HTML comment; not rendered.
5.4	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Values trimmed; only duration: "00:00" quoted (contains colon).
5.5	The filename of the source ER is stated as “er_filename: [er_filename]”	🟢	er_filename: topical_ferulic_acid_skin_2026-0629-1221_Opus_ER.md.
5.6	Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”	🟢	qrs_prompt_version: 26.5.18.
5.7	Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]”	🟢	qrs_creation_date: 2026-0629-1221.
5.8	The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]”	🟢	qrs_creator_ai_nickname: Opus.
5.9	The nickname of the AI is just a single word model name without version, etc.	🟢	“Opus” single word.
5.10	The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]”	🟢	qrs_creator_ai_fullname: Opus 4.8.
5.11	The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier	🟢	“Opus 4.8” — nickname + version.
5.12	The filename of the document is stated as “qrs_filename: [filename of this document]”	🟢	qrs_filename: topical_ferulic_acid_skin_2026-0629-1221_Opus_QRS.html.
5.13	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Frontmatter clean and consistent.

6. Page Title & Header

#	Description	Result	Comments
6.1	[page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet”. The [canonical_topic] is HTML-entity-encoded as needed.	🟢	“Topical Ferulic Acid for Skin Rejuvenation - Quick Reference Sheet” (no entities needed).
6.2	[header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed.	🟢	Matches canonical_topic (line 417).
6.3	[header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]	🟢	“06/29/2026” from 2026-0629.
6.4	[header_subline_model] is set to [qrs_creator_ai_fullname]	🟢	“Opus 4.8” (line 425).
6.5	No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker.	🟢	Header limited to title and subline.

7. At-A-Glance Section

#	Description	Result	Comments
7.1	[at_a_glance] is dense, execution-oriented summary of the ER Conclusion section	🟢	Distills ER Conclusion (lines 390–394).
7.2	[at_a_glance] is no longer than 60 words	🟢	51 words.
7.3	Every fact in [at_a_glance] is supported by a distinct passage in the ER.	🟢	Each clause maps to a Conclusion passage.
7.4	It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead	🟢	“antioxidant”, “vitamin C/E” are plain-language; no specialist acronyms.
7.5	It DOES NOT cite specific trials (names, years, sample sizes, p-values)	🟢	No trial citations.
7.6	It DOES NOT cite effect sizes, relative risks, or statistical results	🟢	“roughly doubling” is qualitative phrasing from the Conclusion, not a numeric effect size or statistic.

8. Contraindications

#	Description	Result	Comments
8.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	Drawn from ER line 260.
8.2	[stop_items] represent the Contraindications from the ER	🟢	Eczema/rosacea flares, broken/resurfaced skin, allergy — all from ER 260.
8.3	Individual [stop_items] are formatted as <li></li>	🟢	Three <li> elements (line 541).
8.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash — these trailing clauses are stripped. Just the key fact.	🟢	Concise; no trailing dash clauses.
8.5	Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible.	🟢	“flares” / “freshly resurfaced” qualifiers preserved.
8.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering), normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	🟢	ER uses no ranking notation; items are plain lists.
8.7	If no [stop_items] are present the section is left empty	N/A	Contraindications are present.

9. Key Interactions

#	Description	Result	Comments
9.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	Drawn from ER lines 250–258.
9.2	[caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications	🟢	Retinoids/acids, OTC AHA/BHA + benzoyl peroxide, post-procedure — no overlap with contraindications.
9.3	Individual [caution_items] are formatted as <li></li>	🟢	Three <li> elements (line 547).
9.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash — these trailing clauses are stripped. Just the key fact.	🟢	Concise; no trailing dash clauses.
9.5	Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible.	🟢	Example drugs (tretinoin, adapalene; glycolic, salicylic) preserved.
9.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering), normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	🟢	No ranking notation in ER; items are plain lists.
9.7	If no [caution_items] are present the section is left empty	N/A	Key interactions are present.

10. Protocol

#	Description	Result	Comments
10.1	The section is derived from the ER Protocol section	🟢	Formulation and timing from ER Protocol (280–288); titration aspect supported by ER.
10.2	The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section	🟢	Formulation, Timing, Titration are the key actionable aspects.
10.3	If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	Three actionable aspects are present and filled.
10.4	All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section.	🟢	All three action cells fully populated from ER.

11. Time to Effect

#	Description	Result	Comments
11.1	The three sets of [time] items cover the three most important time-to-effect aspects from the ER	🟢	Two distinct aspects exist (photoprotection, visible rejuvenation); both captured.
11.2	The sets are picked and ordered by the magnitude of the related benefit	🟢	Photoprotection (Medium tier) before rejuvenation (Low tier).
11.3	If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	🟢	Only two aspects exist; time_3 left empty.
11.4	All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER.	🟢	Both used time cells populated from ER line 329.
11.5	If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel	N/A	ER provides time-to-effect information.

12. Benefits

#	Description	Result	Comments
12.1	The section is derived from the ER Expected Benefits section	🟢	Mirrors ER Expected Benefits tiers (143–179).
12.2	Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]	🟢	All four variables present.
12.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Benefit items reduced to key facts.
12.4	Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	ER “(as part of a vitamin C + E serum)” parenthetical correctly stripped.
12.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with empty-state phrasing.	🟢	benefits_high set to display:none (no High benefits in ER).

13. Risks

#	Description	Result	Comments
13.1	The section is derived from the ER Potential Risks & Side Effects section	🟢	Mirrors ER Risks tiers (208–228).
13.2	Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]	🟢	All four variables present.
13.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Risk items reduced to key facts.
13.4	Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheticals carried through.
13.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with empty-state phrasing.	🟢	risks_high and risks_medium set to display:none (none in ER).

14. Monitoring

#	Description	Result	Comments
14.1	The section is derived from the ER Monitoring section	🟢	Table drawn from ER biomarker table (365–370).
14.2	All measurable/quantifiable biomarkers from the Monitoring section are listed	🟢	Tolerability, visible photoaging, tone evenness, product oxidation — all four listed.
14.3	[monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty.	🟢	Cadence matches ER line 357.

15. Qualitative Assessment

#	Description	Result	Comments
15.1	The section is derived from the ER Monitoring section	🟢	Drawn from ER Monitoring narrative bullets (359–363).
15.2	All subjective/qualitative biomarkers from the Monitoring section are listed	🟢	Tolerability, texture/smoothness, fine lines/firmness, tone evenness, radiance — all five listed.

Issues 29/06/2026 13:46

Pass rate 100.00%. No issues found.

Issues 29/06/2026 13:42

1. 12.4 — Parenthetical content not stripped: benefits_medium (line 525) carries the ER benefit heading’s parenthetical “(as part of a vitamin C + E serum)” through as “Enhanced antioxidant photoprotection as part of a vitamin C + E serum”; item 12.4 requires parenthetical content to be stripped, not preserved.

Fixes 29/06/2026 13:42

1. 12.4 — Parenthetical content stripped: Removed the carried-over parenthetical from benefits_medium, changing “Enhanced antioxidant photoprotection as part of a vitamin C + E serum” to “Enhanced antioxidant photoprotection”.